California Jury Awards $40 Million in Landmark Talc Verdict Against Johnson & Johnson

LOS ANGELES--(BUSINESS WIRE)--A Los Angeles Superior Court jury on Friday delivered a $40 million verdict against Johnson & Johnson. The trial involved two women who developed ovarian cancer after decades of using the company's talc-based baby powder products. The award to plaintiffs Monica Kent and Deborah Schultz, and her husband, Dr. Albert Schultz, totals $40 million in compensatory damages. The California trial is the first of 10 or more trials expected through the first half of 2026 i.

Business Wire • 4 hours ago

Forget the 2.8% Social Security Increase. These Aristocrats Pay You 4% to 7% More Annually

The Social Security Administration announced in October that beneficiaries will receive a 2.8% cost-of-living adjustment (COLA) in 2026, following a 2.5% increase in 2025.

24/7 Wall Street • 3 hours ago

5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine

Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals.

24/7 Wall Street • Dec 13, 2025

Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial

A California jury on Friday awarded $40 million to two women who said Johnson & Johnson's baby powder was to blame for their ovarian cancer.

Reuters • Dec 13, 2025

These Institutional Investors Are Raising Their Stakes in Johnson & Johnson Stock. Should You Do the Same?

A notable bank and a major investment management firm bought more shares of Johnson & Johnson. The healthcare giant has performed well this year despite some significant headwinds.

The Motley Fool • Dec 12, 2025

U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with BRCA2-mutated mCSPC HORSHAM, Pa. , Dec. 12, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).1 Patients with BRCA mutations often have more aggressive forms of prostate cancer leading to poor prognosis, representing a significant unmet need not addressed by previously available therapies.2 "There remains an urgent need for novel therapies for patients with BRCA2-mutated mCSPC, who face significantly faster disease progression and often shorter survival compared to those without the mutation," said Bradley McGregor, M.D.

PRNewsWire • Dec 13, 2025

California Jury Awards $40 Million in Landmark Talc Verdict Against Johnson & Johnson

LOS ANGELES--(BUSINESS WIRE)--A Los Angeles Superior Court jury today delivered a $40 million verdict against Johnson & Johnson. The trial featured two California women who developed ovarian cancer after decades of using the company's talc-based baby powder products. The award to plaintiffs Monica Kent and Deborah Schultz, and her husband, Dr. Albert Schultz, totals $40 million in compensatory damages. The verdict followed a four-week trial that featured testimony from former United States.

Business Wire • Dec 13, 2025

Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider

In the most recent trading session, Johnson & Johnson (JNJ) closed at $210.01, indicating a +1.68% shift from the previous trading day.

Zacks Investment Research • Dec 11, 2025

Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

Johnson & Johnson has surged 14% since my last update, surpassing my $188 target, and now trades near $200. Top-line growth is accelerating, but revenue expansion remains below industry rates and is partially priced in after a strong rally. JNJ's capital structure remains leveraged, clouding its outlook despite progress in positioning for future success.

Seeking Alpha • Dec 12, 2025

5 Dividend Powerhouses That Belong in Every Retirement Portfolio Right Now

For investors approaching or in retirement, the right stock portfolio balances reliable income, low volatility, and consistent dividend growth.

24/7 Wall Street • Dec 10, 2025